Foresite Capital Management Iii is an investment fund managing more than $27.6 million ran by James Tananbaum. There are currently 4 companies in Mr. Tananbaum’s portfolio. The largest investments include Ascendis Pharma A/S and Natera Inc, together worth $18.1 million.
As of 5th August 2022, Foresite Capital Management Iii’s top holding is 133,691 shares of Ascendis Pharma A/S currently worth over $12.4 million and making up 45.1% of the portfolio value.
Relative to the number of outstanding shares of Ascendis Pharma A/S, Foresite Capital Management Iii owns more than approximately 0.1% of the company.
In addition, the fund holds 159,160 shares of Natera Inc worth $5.64 million, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Cymabay Therapeutics Inc worth $4.84 million and the next is Verona Pharma Plc worth $4.66 million, with 1,111,112 shares owned.
Currently, Foresite Capital Management Iii's portfolio is worth at least $27.6 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Foresite Capital Management Iii office and employees reside in Larkspur, California. According to the last 13-F report filed with the SEC, James Tananbaum serves as the Managing Member at Foresite Capital Management Iii.
The two most similar investment funds to Foresite Capital Management Iii are Reliance Trust Co and Tilden Park Management I. They manage $27.5 million and $27.8 million respectively.
Foresite Capital Management Iii’s portfolio is diversified across 1 sector.
Currently, their heaviest sector is Health Care — making up 100.0% of
the total portfolio value.
The fund focuses on investments in the Denmark as
25.0% of the portfolio companies
are based in the Denmark.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $3.01 billion.
These positions were updated on August 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Ascendis Pharma A/S |
No change
133,691
|
$12,428,000 | 45.08% |
| Natera Inc |
No change
159,160
|
$5,641,000 | 20.46% |
| Cymabay Therapeutics Inc |
No change
1,641,804
|
$4,843,000 | 17.57% |
| Verona Pharma Plc |
No change
1,111,112
|
$4,656,000 | 16.89% |
| No transactions found | |||
| Showing first 500 out of 4 holdings | |||